XML 48 R23.htm IDEA: XBRL DOCUMENT v3.7.0.1
Segment Information
 6 Months Ended
Jul. 02, 2016
Segment Reporting [Abstract]  
Segment Information
SEGMENT INFORMATION

Our reporting segments are as follows:

•
CHC is focused primarily on the global sale of OTC store brand products including cough, cold, allergy and sinus, analgesic, gastrointestinal, smoking cessation, infant formula and food, VMS, animal health, and diagnostic products.

•
BCH develops, manufactures, markets and distributes many well-known European OTC brands in the natural health and vitamins, cough, cold and allergy, smoking cessation, personal care and derma-therapeutics, lifestyle, and anti-parasite categories.

•
Rx develops, manufactures and markets a portfolio of generic and specialty pharmaceutical prescription drugs primarily for the U.S. and U.K. markets.

•
Specialty Sciences is comprised primarily of royalties received from assets focused on the management of multiple sclerosis (Tysabri®).

We also have an "Other" segment that is comprised of our API business, which does not meet the quantitative threshold required to be a separately reportable segment. Our segments reflect the way in which our chief operating decision maker reviews our operating results and allocates resources.

The below tables show select financial measures by reporting segment (in millions):
 
 
July 2,
2016
 
December 31, 2015
Total Assets
 
Restated
 
Restated
CHC
 
$
3,748.3

 
$
3,384.8

BCH
 
6,290.7

 
7,083.5

Rx
 
3,340.1

 
2,738.0

Specialty Sciences
 
4,710.1

 
5,930.2

Other
 
202.0

 
213.1

Total
 
$
18,291.2

 
$
19,349.6

 
Three Months Ended
 
July 2, 2016
 
June 27, 2015
 
Restated
 
Restated
 
Total Revenue
 
Operating Income (Loss)
 
Intangible Asset Amortization
 
Total Revenue
 
Operating Income (Loss)
 
Intangible Asset Amortization
CHC
$
686.3

 
$
115.0

 
$
19.0

 
$
746.4

 
$
130.1

 
$
16.6

BCH
343.1

 
(1.8
)
 
39.5

 
368.3

 
16.7

 
34.2

Rx
293.3

 
96.8

 
29.9

 
278.3

 
99.5

 
18.6

Specialty Sciences
—

 
(3.8
)
 
—

 
—

 
(5.2
)
 
0.2

Other
17.8

 
(1.3
)
 
0.5

 
22.2

 
1.9

 
0.5

Unallocated
—

 
(20.1
)
 
—

 
—

 
(50.7
)
 
—

Total
$
1,340.5

 
$
184.8

 
$
88.9

 
$
1,415.2

 
$
192.3

 
$
70.1



 
Six Months Ended
 
July 2, 2016
 
June 27, 2015
 
Restated
 
Restated
 
Total Revenue
 
Operating Income (Loss)
 
Intangible Asset Amortization
 
Total Revenue
 
Operating Income (Loss)
 
Intangible Asset Amortization
CHC
$
1,386.6

 
$
214.5

 
$
38.8

 
$
1,431.3

 
$
234.4

 
$
32.8

BCH*
705.9

 
(400.0
)
 
74.9

 
368.3

 
16.8

 
34.2

Rx
556.9

 
191.1

 
59.4

 
529.9

 
199.5

 
36.9

Specialty Sciences
—

 
(5.1
)
 
—

 
—

 
(8.5
)
 
0.5

Other
38.4

 
4.1

 
1.0

 
52.9

 
12.4

 
0.9

Unallocated
—

 
(51.4
)
 
—

 
—

 
(71.9
)
 
—

Total*
$
2,687.8

 
$
(46.8
)
 
$
174.1

 
$
2,382.4

 
$
382.7

 
$
105.3


*
The BCH segment was created on March 30, 2015 as a result of the Omega acquisition, thus data for the six months ended June 27, 2015 includes only three months of results from operations attributable to Omega.

The Specialty Sciences segment recognized expense (income) of $910.8 million and $69.2 million for the three months ended July 2, 2016 and June 27, 2015, respectively, and $1.1 billion and $(31.5) million for the six months ended July 2, 2016 and June 27, 2015, respectively, for the change in the fair value of the Tysabri® royalty stream during each period.